阿塞西尼布用于新诊断的慢性髓性白血病 - Suppr | 超能文献

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.

作者信息

Gambacorti-Passerini Carlo, Piazza Rocco

机构信息

Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

University of Milano-Bicocca, Monza, Italy.

出版信息

N Engl J Med. 2024 Dec 12;391(23):2274-2275. doi: 10.1056/NEJMc2412813.

DOI:10.1056/NEJMc2412813

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.阿塞西尼布用于新诊断的慢性髓性白血病

N Engl J Med. 2024 Dec 12;391(23):2274-2275. doi: 10.1056/NEJMc2412813.

2

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.阿西替尼治疗新诊断的慢性髓性白血病。

N Engl J Med. 2024 Sep 12;391(10):885-898. doi: 10.1056/NEJMoa2400858. Epub 2024 May 31.

3

Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.阿伐替尼联合伊马替尼、尼洛替尼或达沙替尼治疗慢性期或加速期慢性髓性白血病患者：1期研究最终结果

Leukemia. 2025 May;39(5):1124-1134. doi: 10.1038/s41375-025-02592-9. Epub 2025 Apr 9.

4

Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.阿伐替尼单药治疗新诊断的慢性期慢性髓性白血病：ASC4FIRST III期试验

Future Oncol. 2022 Dec;18(38):4161-4170. doi: 10.2217/fon-2022-0923. Epub 2022 Dec 16.

5

Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.阿伐替尼治疗新诊断慢性髓性白血病患者：ASC4FIRST研究日本亚组的结果

Int J Hematol. 2025 May 26. doi: 10.1007/s12185-025-04014-z.

6

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.阿西替尼单药治疗作为慢性期慢性髓性白血病的一线治疗：ASCEND 研究结果。

Blood. 2024 Nov 7;144(19):1993-2001. doi: 10.1182/blood.2024024657.

7

Asciminib in the treatment of chronic myeloid leukemia in chronic phase.阿伐替尼治疗慢性期慢性髓性白血病

Future Oncol. 2025 Mar;21(7):815-831. doi: 10.1080/14796694.2025.2464494. Epub 2025 Feb 12.

8

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1 treated with at least 2 prior TKIs: Phase 1 final results.Asciminib单药治疗慢性期慢性髓性白血病且未接受过BCR::ABL1治疗但至少接受过2种既往酪氨酸激酶抑制剂治疗的患者：1期最终结果。

Leukemia. 2025 May;39(5):1114-1123. doi: 10.1038/s41375-025-02578-7. Epub 2025 Apr 9.

9

Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.二线和一线 asciminib 在慢性髓性白血病慢性期的剂量递增：ASC2ESCALATE 二期试验。

Future Oncol. 2024;20(38):3065-3075. doi: 10.1080/14796694.2024.2402680. Epub 2024 Oct 10.

10

Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia.阿伐替尼的群体药代动力学建模，以支持慢性髓性白血病患者的暴露-反应和种族敏感性分析。

Cancer Chemother Pharmacol. 2025 Feb 28;95(1):39. doi: 10.1007/s00280-025-04755-y.

引用本文的文献

1

The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysis.阿伐替尼作为慢性髓性白血病二线或二线以上治疗方案治疗患者的疗效和安全性：一项系统评价与荟萃分析

Ther Adv Hematol. 2025 Jun 10;16:20406207251342203. doi: 10.1177/20406207251342203. eCollection 2025.